1. Scrip

Real World Data Helping To Drive Rise Of Novartis' Entresto

 
• By Kevin Grogan

Patients with heart failure on Entresto say they have fewer symptoms and greater quality of life, according to a registry study and Novartis is hoping that this and other real world data will propel the drug towards its peak sales target of $5bn.

Hand holding digital tablet with global network connection technology and modern buildings. Element of this image are furnished by NASA
Entresto real-world data adds to strong clinical package • Source: Shutterstock

After getting off to an extremely slow start, sales of Novartis AG's heart failure drug Entresto (sacubitril/valsartan) are rocketing and the Swiss major has presented more real-world data that it hopes will convince physicians and payers even more about the benefits of the therapy.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas